Concomitant Presence of EGFR and ALK Fusion Gene Mutation in Adenocarcinoma of Lung: A Case Report and Review of the Literature

Nishitha Thumallapally, Hana Yu, Mohammad Farhan, Uroosa Ibrahim, Maricel Odiami

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Empirical evidence has long suggested that oncogenic driver mutations in non-small-cell lung cancer are mutually independent. However, recent studies reported in pertinent literature reveal that concomitant epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangement can occur in a subset of patients with NSCLC. In order to shed further light on this issue, we report a case of adenocarcinoma of lung harboring both EGFR mutation in exon 21 (L861Q) and ALK rearrangement. This allows us to speculate on likely molecular mechanisms underlying this uncommon phenomenon, while also offering some practical guidelines on the therapeutic options that could benefit patients diagnosed with this dual-positive tumor.

Original languageEnglish (US)
Pages (from-to)244-248
Number of pages5
JournalJournal of Pharmacy Practice
Volume31
Issue number2
DOIs
StatePublished - Apr 1 2018
Externally publishedYes

Fingerprint

Gene Fusion
Epidermal Growth Factor Receptor
Mutation
Non-Small Cell Lung Carcinoma
Exons
Guidelines
anaplastic lymphoma kinase
Adenocarcinoma of lung
Neoplasms
Therapeutics

Keywords

  • acquired resistance
  • adenocarcinoma
  • ALK
  • concomitant
  • driver mutation
  • EGFR
  • lung

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Concomitant Presence of EGFR and ALK Fusion Gene Mutation in Adenocarcinoma of Lung : A Case Report and Review of the Literature. / Thumallapally, Nishitha; Yu, Hana; Farhan, Mohammad; Ibrahim, Uroosa; Odiami, Maricel.

In: Journal of Pharmacy Practice, Vol. 31, No. 2, 01.04.2018, p. 244-248.

Research output: Contribution to journalArticle

Thumallapally, Nishitha ; Yu, Hana ; Farhan, Mohammad ; Ibrahim, Uroosa ; Odiami, Maricel. / Concomitant Presence of EGFR and ALK Fusion Gene Mutation in Adenocarcinoma of Lung : A Case Report and Review of the Literature. In: Journal of Pharmacy Practice. 2018 ; Vol. 31, No. 2. pp. 244-248.
@article{0abd0e44885a403ba1289f5085e3d177,
title = "Concomitant Presence of EGFR and ALK Fusion Gene Mutation in Adenocarcinoma of Lung: A Case Report and Review of the Literature",
abstract = "Empirical evidence has long suggested that oncogenic driver mutations in non-small-cell lung cancer are mutually independent. However, recent studies reported in pertinent literature reveal that concomitant epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangement can occur in a subset of patients with NSCLC. In order to shed further light on this issue, we report a case of adenocarcinoma of lung harboring both EGFR mutation in exon 21 (L861Q) and ALK rearrangement. This allows us to speculate on likely molecular mechanisms underlying this uncommon phenomenon, while also offering some practical guidelines on the therapeutic options that could benefit patients diagnosed with this dual-positive tumor.",
keywords = "acquired resistance, adenocarcinoma, ALK, concomitant, driver mutation, EGFR, lung",
author = "Nishitha Thumallapally and Hana Yu and Mohammad Farhan and Uroosa Ibrahim and Maricel Odiami",
year = "2018",
month = "4",
day = "1",
doi = "10.1177/0897190017704751",
language = "English (US)",
volume = "31",
pages = "244--248",
journal = "Journal of Pharmacy Practice",
issn = "0897-1900",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Concomitant Presence of EGFR and ALK Fusion Gene Mutation in Adenocarcinoma of Lung

T2 - A Case Report and Review of the Literature

AU - Thumallapally, Nishitha

AU - Yu, Hana

AU - Farhan, Mohammad

AU - Ibrahim, Uroosa

AU - Odiami, Maricel

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Empirical evidence has long suggested that oncogenic driver mutations in non-small-cell lung cancer are mutually independent. However, recent studies reported in pertinent literature reveal that concomitant epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangement can occur in a subset of patients with NSCLC. In order to shed further light on this issue, we report a case of adenocarcinoma of lung harboring both EGFR mutation in exon 21 (L861Q) and ALK rearrangement. This allows us to speculate on likely molecular mechanisms underlying this uncommon phenomenon, while also offering some practical guidelines on the therapeutic options that could benefit patients diagnosed with this dual-positive tumor.

AB - Empirical evidence has long suggested that oncogenic driver mutations in non-small-cell lung cancer are mutually independent. However, recent studies reported in pertinent literature reveal that concomitant epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangement can occur in a subset of patients with NSCLC. In order to shed further light on this issue, we report a case of adenocarcinoma of lung harboring both EGFR mutation in exon 21 (L861Q) and ALK rearrangement. This allows us to speculate on likely molecular mechanisms underlying this uncommon phenomenon, while also offering some practical guidelines on the therapeutic options that could benefit patients diagnosed with this dual-positive tumor.

KW - acquired resistance

KW - adenocarcinoma

KW - ALK

KW - concomitant

KW - driver mutation

KW - EGFR

KW - lung

UR - http://www.scopus.com/inward/record.url?scp=85043369710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043369710&partnerID=8YFLogxK

U2 - 10.1177/0897190017704751

DO - 10.1177/0897190017704751

M3 - Article

C2 - 28438075

AN - SCOPUS:85043369710

VL - 31

SP - 244

EP - 248

JO - Journal of Pharmacy Practice

JF - Journal of Pharmacy Practice

SN - 0897-1900

IS - 2

ER -